Details werden geladen...
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 | The Manila Times
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1-4, 2026 in Munich, Germany.
Ähnliche Seiten
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 | The Manila Times
https://www.manilatimes.net/2026/05/29/tmt-newswire/globenewswire/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026/2354437Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/ascentage-pharma-releases-latest-clinical-data-from-multiple-trials-at-asco-2026/2349756Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/can-fite-reports-positive-clinical-observation-in-phase-2a-pancreatic-cancer-study-and-highlights-namodenosons-ras-signaling-inhibition-mechanism/2356664
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress | The Manila Times
https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/ascentage-pharma-presents-multiple-clinical-updates-at-eha2026-congress/2365163